Levetiracetam Tablet, Film Coated
Product Images NDC 87441-046

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 87441-046). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Levetiracetam 500 mg (8744104601 Levetiracetam 500 mg)

Levetiracetam 500 mg (8744104601 Levetiracetam 500 mg)
Levetiracetam 500 mg oral film-coated tablets label. The label includes the proprietary and generic name Levetiracetam, strength 500 mg, and dosage form tablets, USP. It notes Rx only status and instructions for pharmacists to dispense the accompanying medication guide. Storage conditions and repackaging information by Unit Dose Solutions, Inc. are displayed, along with distribution by Tuckshoe Enterprises, LLC.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A table presenting dosage recommendations for Levetiracetam based on creatinine clearance levels. It categorizes patients into groups (Normal, Mild, Moderate, Severe, ESRD patients using dialysis) with corresponding creatinine clearance ranges, dosage (mg), and frequency of administration. A note indicates supplemental dosing after dialysis.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to placebo and two doses of Levetiracetam (1000 mg/day and 3000 mg/day). The chart shows 7.4% response for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with statistically significant differences marked for both Levetiracetam groups versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart showing responder rates defined as ≥50% reduction from baseline in Study 2 Period A. The chart compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Asterisks indicate statistically significant differences from placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' compares the percentage of patients responding to placebo and Levetiracetam 3000 mg/day. The placebo group (N=104) shows a 14.4% responder rate, while the Levetiracetam group (N=180) shows a 39.4% responder rate, marked as statistically significant versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart showing responder rates (≥ 50% reduction from baseline) in a study comparing placebo and Levetiracetam. The chart indicates 19.6% responder rate for placebo (N=97) and 44.6% for Levetiracetam (N=101), with a note on statistical significance versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
Bar graph showing responder rates for patients aged 1 month to under 4 years with at least 50% reduction from baseline. It compares placebo (19.6% responders, N=51) to levetiracetam (43.1% responders, N=58) with a statistically significant difference indicated.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' showing the percentage of patients achieving this reduction. The chart compares Placebo with 45.2% responder rate (N=84) and Levetiracetam with 72.2% responder rate (N=79), indicating a statistically significant difference versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam, depicting a 2-oxopyrrolidine ring attached to a chiral carbon bonded to an ethyl group, a hydrogen atom, and a carboxamide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.